The effect of DEBIO 1143 usage alone or in combination with tamoxifen on estrogen receptor positive breast cancer cell lines
No Thumbnail Available
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Purpose: To investigate the effect of increased concentrations of tamoxifen (TAM) and DEBIO 1143 (AT-406) administered alone or in combination on cells in MCF-7 and BT-474 estrogen receptor positive (ER+) breast cancer cell lines. Materials and methods: The effect of tamoxifen and DEBIO 1143 administered alone or in combination on cell viability in MCF-7 and BT-474 cell lines at the 72nd hour was assessed by the XTT test. Multi-parameter apoptosis assay kit was used to display the effect of the alone/combination of TAM and DEBIO 1143 on both cell lines. Fluorescence microscobic analysis was performed. Results: The IC50 value of TAM was 3.8±0.6 micromolar (µM) and 18.9±6.7 µM in the MCF-7 and BT-474 cell lines, respectively. The IC50 value of DEBIO 1143 was 15±0.5 µM in the MCF-7 cell line. The results related to drug combination were statistically significant for both cell lines (p<0.001). The decrease in cell viability was not associated with apoptosis. Conclusion: In ER+breast cancer cell lines, the combined doses of the TAM and DEBIO 1143 reduced cell viability more than their administration alone. Combined administrations in both cell lines were concluded in a synergistic effect. Further research is needed to determine which cell death type other than apoptosis is associated with a reduction in cell viability caused by combined administration.